Treatment of cancers
Case reference FOI2026/06077
Received 16 October 2026
Published 21 October 2026
Request
Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
|
Name of medicine |
|
Number patients treated |
|
1.1 Abiraterone (Zytiga or generic abiraterone) |
|
|
|
1.2 Apalutamide (Erleada) |
|
|
|
1.3 Cabazitaxel |
|
|
|
1.4 Darolutamide (Nubeqa) |
|
|
|
1.5 Docetaxel |
|
|
|
1.6 Enzalutamide (Xtandi) |
|
|
|
1.7 Lutetium-177 PSMA-617 (Pluvicto) |
||
|
1.8 Olaparib (Lynparza) |
|
|
|
1.9 Relugolix (Orgovyx, Ryeqo) |
|
|
|
1.10 Talazoparib (Talzenna) |
|
|
Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
|
Name of medicine |
|
Number patients treated |
|
2.1 Docetaxel for prostate cancer |
|
|
|
2.2 Olaparib (Lynparza) for prostate cancer |
|
|
|
2.3 Talazoparib (Talzenna) for prostate cancer |
|
|
|
2.4 Relugolix (Orgovyx) for prostate cancer |
|
|
Q3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?
|
Name of medicine |
|
Number patients treated in Cycle 1 or Dose 1 |
|
3.1 Abiraterone (Zytiga or generic abiraterone) |
|
|
|
3.2 Apalutamide (Erleada) |
|
|
|
3.3 Cabazitaxel (Jevtana or generic cabazitaxel) |
|
|
|
3.4 Darolutamide (Nubeqa) |
|
|
|
3.5 Enzalutamide (Xtandi) |
|
|
Q4. How many patients were treated with the following combinations in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle.
|
Name of medicine |
|
Total Number patients treated |
|
Number patients received cycle 1 or dose 1 |
|
4.1 Darolutamide (Nubeqa) + Docetaxel |
|
|
|
|
|
4.2 Darolutamide (Nubeqa) monotherapy |
|
|
|
|
|
4.3 Olaparib (Lynparza) + Abiraterone |
|
|
|
|
Q5. How many patients were switched from the following products to darolutamide (Nubeqa) in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
|
Name of medicine |
|
Number patients switched |
|
5.1 Abiraterone |
|
|
|
5.2 Apalutamide |
|
|
|
5.3 Enzalutamide |
Q6. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
|
Name of medicine |
|
Number patients treated |
|
6.1 Abiraterone |
|
|
|
6.2 Enzalutamide |
|
|
Q7. How many patients were treated with darolutamide (Nubeqa) for the following indications and BlueTeq CDF codes between July 2026 to the end of September 2026?
|
BlueTeq CDF code |
BlueTeq CDF description (copied from CDF List) |
Number of patients |
|
DARO1 |
Darolutamide for non-metastatic hormone-resistant (castration-resistant) prostate cancer |
|
|
DARO2 |
Darolutamide in combination with docetaxel and ADT for patients with newly diagnosed metastatic hormone-sensitive prostate cancer |
|
|
DARO3 |
Darolutamide in combination with ADT for patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are unsuitable for treatment with docetaxel |
|
Q8. How many patients received Cemiplimab (Libtayo) for Non-small Cell Lung Cancer in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
|
Product |
|
Number patients treated |
|
8.1 Cemiplimab (Libtayo) for Non-small Cell Lung Cancer |
|
|
Q9. How many patients received Cemiplimab (Libtayo) for Non-small Cell Lung Cancer in combination or as monotherapy in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
|
Combination or monotherapy for Non-small Cell Lung Cancer |
|
Number patients treated |
|
9.1 Cemiplimab + Cisplatin or Carboplatin chemotherapy |
|
|
|
9.2 Cemiplimab monotherapy |
|
|
Q10. How many patients received the following products in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
|
Product |
|
Number patients treated |
|
10.1 Amivantamab (Rybrevant) |
|
|
|
10.2 Lazertinib (Lazcluze) |
||
|
10.3 Osimertinib (Tagrisso) |
|
|
Q11. How many patients received the following products in combination or as monotherapy in the 3 months between July 2026 to the end of September 2026?
|
Product |
|
Number patients treated |
|
11.1 Amivantamab + Lazertinib |
|
|
|
11.2 Amivantamab + Carboplatin + Pemetrexed |
||
|
11.3 Amivantamab Monotherapy |
||
|
11.4 Osimertinib + Pemetrexed + Platinum Chemotherapy |
|
|
|
11.5 Osimertinib Monotherapy |
Q12. How many patients received Osimertinib (Tagrisso) as Adjuvant treatment in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
|
Product |
|
Number patients treated |
|
12.1 Osimertinib as adjuvant treatment |
Response
Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
The timeframe in all cases is 01/05/2026 – 31/07/2026
|
Name of medicine |
|
Number patients treated |
|
1.1 Abiraterone (Zytiga or generic abiraterone) |
|
59 |
|
1.2 Apalutamide (Erleada) |
|
125 |
|
1.3 Cabazitaxel |
|
<5 |
|
1.4 Darolutamide (Nubeqa) |
|
112 |
|
1.5 Docetaxel |
|
64 |
|
1.6 Enzalutamide (Xtandi) |
|
391 |
|
1.7 Lutetium-177 PSMA-617 (Pluvicto) |
22 |
|
|
1.8 Olaparib (Lynparza) |
|
22 |
|
1.9 Relugolix (Orgovyx, Ryeqo) |
|
0 |
|
1.10 Talazoparib (Talzenna) |
|
0 |
Please note: All values given as <5 are done so to prevent this data from being person identifiable. This is done under section 40 (2) of the FOIA.
Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
|
Name of medicine |
|
Number patients treated |
|
2.1 Docetaxel for prostate cancer |
|
20 |
|
2.2 Olaparib (Lynparza) for prostate cancer |
|
0 |
|
2.3 Talazoparib (Talzenna) for prostate cancer |
|
0 |
|
2.4 Relugolix (Orgovyx) for prostate cancer |
|
0 |
Q3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?
|
Name of medicine |
|
Number patients treated in Cycle 1 or Dose 1 |
|
3.1 Abiraterone (Zytiga or generic abiraterone) |
|
21 |
|
3.2 Apalutamide (Erleada) |
|
10 |
|
3.3 Cabazitaxel (Jevtana or generic cabazitaxel) |
|
<5 |
|
3.4 Darolutamide (Nubeqa) |
|
38 |
|
3.5 Enzalutamide (Xtandi) |
|
18 |
Please note: All values given as <5 are done so to prevent this data from being person identifiable. This is done under section 40 (2) of the FOIA.
Q4. How many patients were treated with the following combinations in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle.
|
Name of medicine |
|
Total Number patients treated |
|
Number patients received cycle 1 or dose 1 |
|
4.1 Darolutamide (Nubeqa) + Docetaxel |
|
16 |
|
8 |
|
4.2 Darolutamide (Nubeqa) monotherapy |
|
112 |
|
38 |
|
4.3 Olaparib (Lynparza) + Abiraterone |
|
0 |
|
0 |
Q5. How many patients were switched from the following products to darolutamide (Nubeqa) in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
|
Name of medicine |
|
Number patients switched |
|
5.1 Abiraterone |
|
0 |
|
5.2 Apalutamide |
|
0 |
|
5.3 Enzalutamide |
<5 |
Please note: All values given as <5 are done so to prevent this data from being person identifiable. This is done under section 40 (2) of the FOIA.
Q6. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
We cannot specify with any more detail than ICD-10 codes, so we have answered the below for all “prostate cancer” diagnoses
|
Name of medicine |
|
Number patients treated |
|
6.1 Abiraterone |
|
58 |
|
6.2 Enzalutamide |
|
384 |
Q7. How many patients were treated with darolutamide (Nubeqa) for the following indications and BlueTeq CDF codes between July 2026 to the end of September 2026?
We cannot specify with any more detail than ICD-10 codes, so we have answered the below for all “prostate cancer” diagnoses
|
BlueTeq CDF code |
BlueTeq CDF description (copied from CDF List) |
Number of patients |
|
DARO1 |
Darolutamide for non-metastatic hormone-resistant (castration-resistant) prostate cancer |
111 |
|
DARO2 |
Darolutamide in combination with docetaxel and ADT for patients with newly diagnosed metastatic hormone-sensitive prostate cancer |
0 |
|
DARO3 |
Darolutamide in combination with ADT for patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are unsuitable for treatment with docetaxel |
0 |
Q8. How many patients received Cemiplimab (Libtayo) for Non-small Cell Lung Cancer in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
We cannot specify with any more detail than ICD-10 codes, so we have answered the below for all “lung cancer” diagnoses
|
Product |
|
Number patients treated |
|
8.1 Cemiplimab (Libtayo) for Non-small Cell Lung Cancer |
|
0 |
Q9. How many patients received Cemiplimab (Libtayo) for Non-small Cell Lung Cancer in combination or as monotherapy in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
We cannot specify with any more detail than ICD-10 codes, so we have answered the below for all “lung cancer” diagnoses
|
Combination or monotherapy for Non-small Cell Lung Cancer |
|
Number patients treated |
|
9.1 Cemiplimab + Cisplatin or Carboplatin chemotherapy |
|
0 |
|
9.2 Cemiplimab monotherapy |
|
0 |
Q10. How many patients received the following products in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
|
Product |
|
Number patients treated |
|
10.1 Amivantamab (Rybrevant) |
|
0 |
|
10.2 Lazertinib (Lazcluze) |
0 |
|
|
10.3 Osimertinib (Tagrisso) |
|
37 |
Q11. How many patients received the following products in combination or as monotherapy in the 3 months between July 2026 to the end of September 2026?
|
Product |
|
Number patients treated |
|
11.1 Amivantamab + Lazertinib |
|
0 |
|
11.2 Amivantamab + Carboplatin + Pemetrexed |
0 |
|
|
11.3 Amivantamab Monotherapy |
0 |
|
|
11.4 Osimertinib + Pemetrexed + Platinum Chemotherapy |
|
<5 |
|
11.5 Osimertinib Monotherapy |
37 |
Please note: All values given as <5 are done so to prevent this data from being person identifiable. This is done under section 40 (2) of the FOIA.
Q12. How many patients received Osimertinib (Tagrisso) as Adjuvant treatment in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?
|
Product |
|
Number patients treated |
|
12.1 Osimertinib as adjuvant treatment |
7 |
Documents
This is Oxford University Hospitals NHS Foundation Trust's response to a freedom of information (FOI) or environmental information regulations (EIR) request.
You can browse our other responses or make a new FOI request.